Premium
A novel protein glycan biomarker and LCAT activity in metabolic syndrome
Author(s) -
Gruppen Eke G.,
Connelly Margery A.,
Otvos James D.,
Bakker Stephan J.L.,
Dullaart Robin P.F.
Publication year - 2015
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12481
Subject(s) - medicine , endocrinology , biomarker , serum amyloid a , acute phase protein , inflammation , c reactive protein , cholesterol , metabolic syndrome , lipoprotein , diabetes mellitus , biology , biochemistry
Background The cholesterol‐esterifying enzyme, lecithin:cholesterol acyltransferase ( LCAT ), is instrumental in high‐density lipoprotein ( HDL ) remodelling. LCAT may also modify oxidative and inflammatory processes, as supported by an inverse relationship with HDL antioxidative functionality and a positive relationship with high‐sensitivity C‐reactive protein (hs CRP ). GlycA is a recently developed proton nuclear magnetic resonance ( NMR ) spectroscopy‐measured biomarker of inflammation whose signal originates from a subset of N ‐acetylglucosamine residues on the most abundant glycosylated acute‐phase proteins. Plasma GlycA correlates positively with hs CRP and may predict cardiovascular disease even independent of hs CRP . Here, we tested the extent to which plasma GlycA is elevated in metabolic syndrome (MetS), and determined its relationship with LCAT activity. Materials and methods Plasma GlycA, hs CRP , serum amyloid A ( SAA ), tumour necrosis factor‐α ( TNF ‐α) and LCAT activity were measured in 58 subjects with MetS (including 46 subjects with type 2 diabetes mellitus (T2 DM )) and in 45 nondiabetic subjects without MetS. Results Plasma GlycA was higher in MetS coinciding with higher hs CRP and LCAT activity ( P < 0·01 for each). In all subjects combined, GlycA was correlated positively with hs CRP , SAA and LCAT activity ( P < 0·001 for each), but not with TNF ‐α. Age‐ and sex‐adjusted multivariable linear regression analysis revealed that GlycA was positively associated with LCAT activity ( P = 0·029), independent of the presence of MetS, T2 DM , hs CRP and SAA . GlycA was unrelated to diabetes status. Conclusion A pro‐inflammatory glycoprotein biomarker, GlycA, is higher in MetS. Higher plasma levels of this glycoprotein biomarker relate to increased LCAT activity in the setting of MetS.